ArticlePediatric blood & cancer2025
Seeing the Bigger Picture: Cytomegalovirus Retinitis Screening in Pediatric Hematopoietic Stem Cell Transplant Patients.
Article in Pediatric blood & cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionCytomegalovirus (CMV) reactivation poses significant risks in pediatric patients undergoing allogeneic hematopoietic stem cell transplant (HSCT), including the potential for CMV retinitis, which can cause severe ocular complications. A previously published CMV retinitis screening protocol called for intensive and frequent screening exams with retinal photography.
objectivesTo evaluate the prevalence and incidence of CMV retinitis, assess institutional adherence to previously published protocol, and determine the impact and efficacy of the CMV retinitis screening protocol.
methodsRetrospective cohort study of 228 patients treated at Children's Hospital Colorado from 2015 to 2021.
resultsAmong allogeneic HSCT patients, 25.4% developed CMV viremia, and of these, three developed CMV retinitis (mean time from viremia to retinitis diagnosis: 53.6 days). Adherence to the protocol was suboptimal; 27.6% of patients with CMV viremia underwent recommended dilated fundus exam and photography within 2 weeks of diagnosis. Despite this, no significant long-term ocular complications were noted, suggesting limited benefit from early and frequent screenings.
conclusionsWithin this cohort, 5.2% of patients with CMV viremia developed retinitis, and 15.4% of all patients developed at least one ocular complication. Universal pre-HSCT screening with fundus photography did not result in early detection of retinitis. In this cohort, CMV retinitis did not develop until 5-12 weeks after viremia was detected, making early screening unlikely to have clinical significance. This study highlights the necessity of ocular screenings-as all patients with CMV retinitis were asymptomatic-but advocates for a more streamlined approach to improve adherence and protect ocular health during the vulnerable post-transplant period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.